Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Other financing activities (2016 - 2022)

Historic Other financing activities for Bio-Techne (TECH) over the last 14 years, with Q3 2022 value amounting to -$2.5 million.

  • Bio-Techne's Other financing activities rose 8943.04% to -$2.5 million in Q3 2022 from the same period last year, while for Jun 2023 it was -$2.5 million, marking a year-over-year increase of 8212.57%. This contributed to the annual value of -$2.5 million for FY2023, which is 41180.2% down from last year.
  • Per Bio-Techne's latest filing, its Other financing activities stood at -$2.5 million for Q3 2022, which was up 8943.04% from $3.4 million recorded in Q1 2022.
  • Bio-Techne's 5-year Other financing activities high stood at $11.7 million for Q1 2021, and its period low was -$23.2 million during Q3 2021.
  • Moreover, its 5-year median value for Other financing activities was $2.8 million (2019), whereas its average is $1.5 million.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 214948.45% in 2018, then surged by 113333.33% in 2019.
  • Over the past 5 years, Bio-Techne's Other financing activities (Quarter) stood at $300000.0 in 2018, then skyrocketed by 1133.33% to $3.7 million in 2019, then rose by 29.73% to $4.8 million in 2020, then increased by 27.08% to $6.1 million in 2021, then tumbled by 140.28% to -$2.5 million in 2022.
  • Its last three reported values are -$2.5 million in Q3 2022, $3.4 million for Q1 2022, and $6.1 million during Q4 2021.